• Corpus ID: 20599042

Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.

@article{Bhalla1992EffectOC,
  title={Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.},
  author={Kapil N. Bhalla and Gloria Bullock and Jose Lutzky and Charles Holladay and Ana Maria Ibrado and Michelle Jasiok and S. Singh},
  journal={Leukemia},
  year={1992},
  volume={6 8},
  pages={
          814-9
        }
}
4-Hydroperoxycyclophosphamide (4-HC) is widely used as an ex vivo bone marrow purging agent for acute myeloid leukemia (AML) blasts. We have determined the effect of a combined treatment with interleukin 3 (IL-3) plus IL-6 on 4-HC cytotoxicity against normal (CFU-GEMM) versus AML (L-CFU) bone marrow progenitor cells. Following an 18 h exposure to IL-3 plus IL-6, treatment with 4-HC in conjunction with IL-3 and IL-6 for one hour resulted in a significantly greater inhibition of L-CFU versus CFU… 
Improved Antileukemic Activity of the Combination of Ara-C with GM-CSF and IL-3 Fusion Protein (PIXY321)
TLDR
None of these modulations of Ara-C-induced apoptosis in the leukemic or normal cells was associated with appreciable alterations in intracellular p26BCL-2 levels.
Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells
TLDR
The data suggest that GSH plays a critical role in the growth-promoting effects of IL-2 on B16F10 melanoma cells and in the antagonistic effect of IL -2 on CY inhibitory activity on these tumor cells.
Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.
TLDR
It is shown that anti-IL-6 mAb sensitized CDDP-resistant K562 cells to CDDP by induction of apoptotic death and the reduction of glutathione levels might be implicated in the enhanced cytotoxicity observed.
l-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases
TLDR
It is found that OTZ, by depressing GSH levels, abrogates the in vitro growth-promoting effects of IL2 on B16 melanoma cells, and markedly protected mice against CY-induced toxicity, which allowed the administration of otherwise lethal doses of CY.
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients
TLDR
Considerable interpatient variability exists in the pharmacokinetic and drug-specific biomarkers potentially relevant to clinical outcomes in HLA-haploidentical HCT recipients, and pharmacodynamic studies are warranted to optimize the conditioning regimen and postgrafting immunosuppression administered to HLA/HCT recipients.